Recombinetics, founded in 2008 and based in St. Paul, Minnesota, is a bio-engineering company specializing in gene editing solutions. The company focuses on developing technologies for biomedical research, regenerative medicine, and animal agriculture. Its notable products include genetically engineered hornless cattle and efforts to grow human organs and tissues in pigs. Recombinetics leverages its proprietary gene editing platform through four subsidiaries to impact human health and farm animal value.
Under the leadership of CEO Mark Platt, Recombinetics has raised $31 million from private investors. The company is recognized for its innovative contributions to healthcare and agriculture, particularly in creating genetically engineered livestock. Its advancements in gene editing have positioned it as a leader in the field, driving significant progress in both medical research and agricultural practices.
